人才隊伍
返回列表
高磊
研究生培養(yǎng)
培養(yǎng)碩士生6人，博士研究生6人。1人被評為北京協(xié)和醫(yī)學(xué)院優(yōu)秀畢業(yè)生，1人被評為北京市優(yōu)秀畢業(yè)生。
個人簡介
中國醫(yī)學(xué)科學(xué)院/北京協(xié)和醫(yī)學(xué)院病原生物學(xué)研究所副所長，課題組長。主要從事傳染病流行病學(xué)研究，重點探索適宜中國結(jié)核病高負擔(dān)國情的結(jié)核潛伏感染人群預(yù)防干預(yù)新技術(shù)和新方案。入選教育部新世紀優(yōu)秀人才、北京市科技新星、協(xié)和新星等。國家傳染病標準專業(yè)委員會委員、中國防癆協(xié)會結(jié)核潛伏感染防治專業(yè)分會副主任委員、中國防癆協(xié)會標準化專業(yè)分會秘書長、第一批國家健康科普專家?guī)斐蓡T。中華結(jié)核和呼吸雜志、中國防癆雜志、BMC Infectious Diseases、PLOS Global Public Health、Chronic Diseases and Translational Medicine等學(xué)術(shù)期刊編委。作為第一作者或通訊作者在Lancet Infect Diseases，European Respiratory Journal等國際學(xué)術(shù)期刊發(fā)表SCI論文50余篇。獲中華預(yù)防醫(yī)學(xué)會科學(xué)技術(shù)一等獎、中國防癆協(xié)會科學(xué)技術(shù)一等獎、中華醫(yī)學(xué)科學(xué)技術(shù)二等獎、高等學(xué)?？茖W(xué)研究優(yōu)秀成果獎自然科學(xué)類二等獎、中國醫(yī)學(xué)科學(xué)院“杰出貢獻獎”、中國醫(yī)學(xué)科學(xué)院-法國梅里埃研究院“青年科學(xué)家獎”等。
研究方向
結(jié)核病等重大傳染病的流行病學(xué)和精準干預(yù)研究
科研項目
1、傳染病防治科技重大項目，2017ZX10201302-009，結(jié)核潛伏感染干預(yù)治療效果研究 ，子課題負責(zé)人
2、傳染病防治科技重大項目，2017ZX10201302-00，肺結(jié)核人工智能影像診斷系統(tǒng)的優(yōu)化升級，子課題負責(zé)人
3、中國醫(yī)學(xué)科學(xué)院醫(yī)學(xué)與健康科技創(chuàng)新工程，2019-I2M-2-005，農(nóng)村中老年人群結(jié)核潛伏感染流行病學(xué)調(diào)查和干預(yù)研究隊列，課題負責(zé)人
4、傳染病防治科技重大項目，2017ZX10201302002，既往肺結(jié)核患者潛伏感染干預(yù)手段研究，子課題負責(zé)人
研究成果
1、Gao L, Lu W, Bai L, Wang X, Xu J, Catanzaro A, Cárdenas V, Li X, Yang Y, Du J, Sui H, Xia Y, Li M, Feng B, Li Z, Xin H, Zhao R, Liu J, Pan S, Shen F, He J, Yang S, Si H, Wang Y, Xu Z, Tan Y, Chen T, Xu W, Peng H, Wang Z, Zhu T, Zhou F, Liu H, Zhao Y, Cheng S, Jin Q; LATENTTB-NSTM study team. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2015 Mar;15(3):310-9.
2、Gao L, Li X, Liu J, Wang X, Lu W, Bai L, Xin H, Zhang H, Li H, Zhang Z, Ma Y, Li M, Feng B, Du J, Sui H, Zhao R, Su H, Pan S, Guan L, Shen F, He J, Yang S, Si H, Cheng X, Xu Z, Tan Y, Chen T, Xu W, Peng H, Wang Z, Zhu T, Chen X, Zhou X, Guan X, Jin Q; LATENTTB-NSTM study team. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017 Oct;17(10):1053-1061.
3、Zhang H, Xin H, Li X, Li H, Li M, Feng B, Gao L*. Reversion of QuantiFERON-TB Gold In-Tube test in individuals with and without prophylactic treatment for latent tuberculosis infection: A systematic review and meta-analysis. J Infect. 2018 Oct;77(4):276-282.
4、Zhang H, Xin H, Wang D, Pan S, Liu Z, Cao X, Wang J, Li X, Feng B, Li M, Yang Q, Zhang M, Jin Q, Gao L*. Serial testing of mycobacterium tuberculosis infection in Chinese village doctors by QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold In-Tube and T-SPOT.TB. J Infect. 2019;78(4):305-10.
5、Xin H, Zhang H, Cao X, Li X, Li M, Feng B, Jin Q, Gao L*. Serum level of IL-8 is associated with reversion of QuantiFERON-TB gold in-tube tests. J Infect. 2019 Apr;78(4):292-298.
6、Gao L*, Bai L, Liu J, Lu W, Wang X, Li X, Du J, Chen X, Zhang H, Xin H, Sui H, Li H, Su H, He J, Pan S, Peng H, Xu Z, Catanzaro A, Evans TG, Zhang Z, Ma Y, Li M, Feng B, Li Z, Guan L, Shen F, Wang Z, Zhu T, Yang S, Si H, Wang Y, Tan Y, Chen T, Chen C, Xia Y, Cheng S, Xu W, Jin Q*; LATENTTB-NSTM study team. Annual risk of tuberculosis infection in rural China: a population-based prospective study. Eur Respir J. 2016;48(1):168-78.
7、Gao L*, Zhang H, Xin H, Liu J, Pan S, Li X, Guan L, Shen F, Liu Z, Wang D, Guan X, Yan J, Li H, Feng B, Cao X, Chen Y, Cui W, Zhang Z, Ma Y, Chen X, Zhou X, Jin Q*; LATENTTB-NSTM study team. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J. 2018 Dec 20;52(6):1801470.
8、Xin H, Cao X, Zhang H, Feng B, Du Y, Zhang B, Wang D, Liu Z, Guan L, Shen F, Guan X, Yan J, He Y, He Y, Quan Z, Pan S, Liu J, Jin Q, Gao L*. Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial. Eur Respir J. 2022 Jul 7;60(1):2102359.
9、Xin H, Cao X, Zhang H, Liu J, Pan S, Li X, Guan L, Shen F, Liu Z, Wang D, Guan X, Yan J, Li H, Feng B, Zhang M, Yang Q, Jin Q, Gao L*; LATENTTB-NSTM study team. Dynamic changes of interferon gamma release assay results with latent tuberculosis infection treatment. Clin Microbiol Infect. 2020;26(11):p1555.e1-7.
10、Xin H, Zhang H, Liu J, Pan S, Li X, Cao X, Feng B, Guan L, Shen F, Liu Z, Wang D, Yan J, Zhang M, Yang Q, Jin Q, Gao L*. Tuberculosis infection among the elderly in 20,486 rural residents aged 50-70 years old in Zhongmu County, China. Clin Microbiol Infect. 2019;25(9):1120-6.
11、Zhang H, Xin H, Du Y, Cao X, Pan S, Liu J, Guan L, Shen F, Liu Z, Zhang B, Wang D, Feng B, Du J, Guan X, He Y, He Y, Zhang Z, Yan J, Jin Q, Gao L*; LATENTTB TRIAL2-NSTM study team. Tuberculosis preventive treatment among individuals with inactive tuberculosis suggested by untreated radiographic abnormalities: a community-based randomized controlled trial. Emerg Microbes Infect. 2023 Dec;12(1):e2169195.
12、Xin H, Zhang H, Yang S, Liu J, Lu Wei, Bai L, Cao X, Feng B, Jin Q, Gao L*. 5-year follow-up of active tuberculosis development from latent infection in rural China. Clin Infect Dis. 2020;70(5):947-50.
13、Li H, Xin H, Qian S, Li X, Zhang H, Li M, Feng B, Jin Q, Gao L*. The testing of tuberculosis infection among the adolescents born after booster Bacillus Calmette-Guérin vaccination was terminated in China: Subgroup analysis of a population-based cross-sectional study. Front Med. 2017;11(4):528-535.
14、Li X, Yang Y, Liu J, Zhou F, Cui W, Guan L, Shen F, Gao C, Li M, Jin Q*, Gao L*. Treatment outcomes of pulmonary tuberculosis in the past decade in the mainland of China: a meta-analysis. Front Med. 2013;7(3):354-66.
15、He Y, Cao X, Guo T, He Y, Du Y, Zhang H, Feng B, Du J, Zhang B, Wang K, Yan J, Wang D, Liu Z, Pan S, Xin H*, Gao L*. Serial testing of latent tuberculosis infection in patients with diabetes mellitus using interferon-gamma release assay, tuberculin skin test, and creation tuberculin skin test. Front. Public Health. 2022. 10:1025550.